The British scientist’s company employs artificial intelligence to drastically reduce the speed of drug development
It was early one morning in 1996 when Andrew Hopkins, then a PhD biophysics student at Oxford University, had a brainwave as he walked home from a late-night lab meeting.
He was trying to find molecules to fight HIV and to better understand drug resistance.
